TX-MAVENIR
Pardeep Kohli, CEO of Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has today welcomed the new ranking by global technology intelligence company ABI Research that recognizes Mavenir as the leading vendor in Open Radio Access Network (Open RAN) solutions. In ABI Research’s detailed and independent Competitive Assessment vendor matrix, Mavenir tops all three ranking categories – market leadership, innovation and implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206233989/en/
ABI Research Open RAN Vendor Ranking November 2023 (Graphic: Business Wire)
Mavenir is classed as the leading innovator in the Open RAN space with an impressive score of 81.5 out of 100, while its achievement of 84.5 out of 100 in the implementation criteria reflects Mavenir’s central role in accelerating Open RAN deployments globally. These key rankings position Mavenir as the overall global market leader for Open RAN in the ABI Research assessment framework.
Commenting on Mavenir’s stand-out performance in the global vendor analysis, Mavenir CEO Pardeep Kohli said: “I wholeheartedly welcome this recognition of our market leadership by ABI Research, following a robust and impartial assessment of both new and incumbent players. This pole-position ranking – delivered through ABI Research’s respected and transparent process – is a significant endorsement of our dedicated mission to create the market conditions, forge the industry partnerships and deliver the technology innovation to accelerate ubiquitous and large-scale Open RAN deployments, generating powerful gains for operators and users alike.”
Using a rigorous and thorough assessment framework, ABI Research has evaluated the leading Open RAN vendors to provide a comprehensive and authoritative picture of the competitive dynamics of the Open RAN vendor ecosystem. The core areas of analysis span ten criteria, segmented across innovation and implementation clusters – including R&D activities, O-RAN Alliance contributions, support for mMIMO, recent commercial momentum, product portfolio, geographical coverage, partnerships and memberships, PoCs/trials/testing, energy efficiency commitments and brownfield deployments – concluding with an in-depth profile of the implementation and innovation strategies of the major market players.
Saqlain Ali, Senior Analyst at ABI Research remarked: “Mavenir ranked overall leader in the competitor ranking and earned the top spots for both innovation and implementation. Mavenir has demonstrated its role as a leading Open RAN vendor due to its end-to-end cloud-native software and hardware and O-RAN Alliance-compliant solutions.”
He added: “Mavenir has made significant efforts to accelerate Open RAN deployments in partnerships with other mobile, chipset vendors, and cloud providers to validate its Open RAN portfolio for multi-vendor deployments. Mavenir’s customer base is diverse, with Mavenir serving 300+ CSPs in more than 120 countries.”
The report authors highlight several areas where Mavenir is demonstrating its role as a leading industry innovator in the Open RAN domain, including its provision of end-to-end cloud-native software and hardware solutions with a comprehensive portfolio covering the core, edge and Open RAN. Further emphasized in the framework are Mavenir’s open and fully virtualized RAN (vRAN), its O-RAN Alliance-compliant solution designed to support Open RAN Functional Split (FS) options, plus Mavenir’s OpenBeam™ mMIMO portfolio, which supports both the 3rd Generation Partnership Project (3GPP) and O-RAN Alliance-compliant radios.
Mavenir’s clear commercial momentum during 2023 is a key factor in its top-ranking performance, including its announcement of multiple successful trials and new strategic partnerships with CSPs, cloud providers, and chipset vendors. The assessors particularly note the expansion of Mavenir’s geographical coverage in supporting major mobile operators with Open RAN deployment. Finally, the report draws attention to the considerable breadth of Mavenir’s partner ecosystem, plus its active collaboration with cloud providers, chipset vendors, mobile vendors, and operators to perform Open RAN integration and interoperability testing.
Notes to editors:
- ABI Research, Open RAN Vendor Assessment: Mavenir
© 2023 ABI Research. Distributed with permission of ABI Research. ABI Research Competitive Ranking, Open RAN Portfolio: November 2023
About ABI Research:
ABI Research is a global technology intelligence firm delivering actionable research and strategic guidance to technology leaders, innovators, and decision makers around the world. Our research focuses on the transformative technologies that are dramatically reshaping industries, economies, and workforces today.
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206233989/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom